Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
DiObex logo — Innovative biotechnology solutions for metabolic disorders.

DiObex

Innovative biotechnology solutions for metabolic disorders.

Founded 2003 Series B Total: $31.08M Biotechnology, Health Care

General Information

Company Name DiObex
Founded Year 2003
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with DiObex. To contact DiObex, visit diobex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DiObex compare?

A PDF of DiObex and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DiObex soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DiObex

DiObex is a San Francisco-based biotechnology startup established in 2003 with a focus on developing innovative treatments for metabolic conditions such as type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. The company's flagship products include DIO-901, a very low dose glucagon product aimed at reducing nocturnal hypoglycemia in type-one diabetes patients, and DIO-902, a cortisol synthesis inhibitor designed to manage glucose and cholesterol levels in patients with type-two diabetes. The last recorded investment for DiObex was a significant $24.00M Series B investment on 16 April 2007, led by Domain Associates, Sofinnova Investments, Mitsui Global Investment, Pac-Link, Inventages, and Pequot Capital. With a dedication to addressing unmet medical needs in the metabolic disorder space, DiObex positions itself as a compelling player in the biotechnology and healthcare sectors.

Business keywords: Metabolic Disorders, Innovative Treatments, Type-One Diabetes, Type-Two Diabetes, Dyslipidemia, Obesity, Diabetic Nephropathy, Glucagon Product, Cortisol Synthesis Inhibitor, San Francisco, Research and Development, Biopharmaceuticals, Healthcare Innovation, Clinical Trials

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $24.00M 6
Domain Associates Sofinnova Investments Mitsui Global Investment
Domain Associates, Sofinnova Investments +4
16 Apr 2007
Series A $7.08M 3
Domain Associates Sofinnova Investments
Domain Associates, Sofinnova Investments +1
16 Sep 2005

DiObex Alternatives & Competitors

View All Alternatives
DiObex vs
Ardelyx, Inc.
Ardelyx, Inc. United States

Translating Scientific Breakthroughs into Promise for Patients

Post-IPO Debt
378 employees
Biotechnology, Health Care
Compare DiObex vs Ardelyx, Inc.
DiObex vs
Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals China

Science & Excellence

Private Equity
379 employees
Biopharma, Biotechnology
DiObex vs
Phenomix
Phenomix

A pioneering biotech company dedicated to developing groundbreaking therapies for diabetes and hepat...

Venture round
Biotechnology, Health Care
View all alternatives

FAQ About DiObex

Innovative biotechnology solutions for metabolic disorders.
DiObex was founded in 2003.
DiObex operates in Biotechnology and Health Care. Its work centres on Metabolic Disorders, Innovative Treatments, Type-One Diabetes and Type-Two Diabetes.
DiObex has completed 2 funding rounds, raising a total of $31.08M. The latest funding stage is Series B.
Top alternatives and competitors to DiObex include Ardelyx, Inc., Gan & Lee Pharmaceuticals, Phenomix, Morphic Medical, Inversago Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DiObex and Ardelyx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DiObex, https://bouncewatch.com/company/diobex, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes